Apolipoprotein C-III is an Amyloid-β-Binding Protein and an Early Marker for Alzheimer's Disease
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
It has been demonstrated that peripheral injection of anti-amyloid-β (Aβ) antibodies to patients with Alzheimer's disease (AD) and AD transgenic mice facilitate Aβ clearance. We hypothesized that peripheral circulating Aβ-binding proteins also possess the ability to enhance Aβ clearance and the levels of circulating Aβ-binding proteins could serve as early AD biomarkers. Circulating Aβ-binding proteins were isolated from plasma and identified by LC-MS/MS. Their levels were compared among non-demented individuals without AD family history (ND), with AD family history (ND-FH), and patients with mild AD. The results showed that most of the identified Aβ-binding proteins were apolipoproteins, i.e., apoA-I, apoB-100, apoC-III, and apoE. Aβ bound preferentially to apoA-I-enriched HDL, followed by apoC-III- and apoE-enriched VLDL, and bound less favorably to apoB-100-enriched LDL. Levels of apoA-I were reduced in AD patients and could be used to discriminate AD from ND groups (AUC: 0.93); whereas levels of apoC-III were reduced in both ND-FH and AD groups and could be used to differentiate ND-FH from ND individuals (AUC: 0.81). Both the levels of apoA-1 and apoC-III positively correlated with CASI and MMSE scores. In conclusion, these results suggest that plasma apoA-I could be a sensitive AD biomarker and individuals with low plasma levels of apoC-III are at risk for AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moms, J. C., Heyman, A., Mohs, R. C., Hughes, J. P., van Belle, G., Fillenbaum, G., Mellits, E. D., & Clark, C. (1989) · Neurology · doi:10.1212/wnl.39.9.1159 · Cited by 4,130
Gorelick, P. B., Scuteri, A., Black, S. E., DeCarli, C., Greenberg, S. M., Iadecola, C., Launer, L. J., Laurent, S., Lopez, O. L., Nyenhuis, D., et al. (2011) · Stroke · doi:10.1161/str.0b013e3182299496 · Cited by 3,811
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease
Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., & Bateman, R. J. (2010) · Science · doi:10.1126/science.1197623 · Cited by 2,078 · cited 1×
“A recent study using metabolic labeling demonstrated that while the production rates of A 40 and A 42 were comparable between AD patients and agematched cognitively normal controls, the clearance rates of these two forms of A were reduced in the AD patients [11].”
Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids
Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., et al. (1992) · Nature · doi:10.1038/359325a0 · Cited by 1,731
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events
Barter, P., Gotto, A. M., LaRosa, J. C., Maroni, J., Szarek, M., Grundy, S. M., Kastelein, J. J. P., Bittner, V., & Fruchart, J.-C. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa064278 · Cited by 1,610
Shibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10498 · Cited by 1,413 · cited 1×
“This hypothesis is based on findings of active A transport across the blood-brain barrier through low-density lipoprotein receptor-related protein (LRP) from the CNS into the periphery [17, 18].”
Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report
Nicoll, J. A. R., Wilkinson, D., Holmes, C., Steart, P., Markham, H., & Weller, R. O. (2003) · Nature Medicine · doi:10.1038/nm840 · Cited by 1,397 · cited 1×
“A immunization was found effectively reducing brain amyloid plaques [12, 13].”
Water-soluble Aβ(N-40, N-42) oligomers in normal and Alzheimer disease brains
Kuo, Y.-M., Emmerling, M. R., Vigo-Pelfrey, C., Kasunic, T. C., Kirkpatrick, J. B., Murdoch, G. H., Ball, M. J., & Roher, A. E. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.8.4077 · Cited by 618
Self-citationDeMattos, R. B., Bales, K. R., Cummins, D. J., Paul, S. M., & Holtzman, D. M. (2002) · Science · doi:10.1126/science.1067568 · Cited by 563
Cited by
HDL from an Alzheimer's disease perspective
Button, E. B., Robert, J., Caffrey, T. M., Fan, J., Zhao, W., & Wellington, C. L. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000604 · Cited by 114
Patir, A., Shih, B., McColl, B. W., & Freeman, T. C. (2019) · Glia · doi:10.1002/glia.23572 · Cited by 90
Midlife lipid and glucose levels are associated with Alzheimer's disease
Zhang, X., Tong, T., Chang, A., Ang, T. F. A., Tao, Q., Auerbach, S., Devine, S., Qiu, W. Q., Mez, J., Massaro, J., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12641 · Cited by 65
Urinary Apolipoprotein C3 Is a Potential Biomarker for Alzheimer’s Disease
Watanabe, Y., Hirao, Y., Kasuga, K., Tokutake, T., Kitamura, K., Niida, S., Ikeuchi, T., Nakamura, K., & Yamamoto, T. (2020) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000509561 · Cited by 38
Lee, M., Shih, Y., Lin, S., Chang, J., Lin, Y., Sze, C., Kuo, Y., & Chang, N. (2017) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.02.001 · Cited by 37
Self-citationRelation between plasma and brain lipids
Wellington, C. L., & Frikke-Schmidt, R. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000291 · Cited by 33
Apolipoproteins and their subspecies in human cerebrospinal fluid and plasma
Koch, M., Furtado, J. D., Falk, K., Leypoldt, F., Mukamal, K. J., & Jensen, M. K. (2017) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2017.01.007 · Cited by 31
Robert, J., Button, E. B., Martin, E. M., McAlary, L., Gidden, Z., Gilmour, M., Boyce, G., Caffrey, T. M., Agbay, A., Clark, A., et al. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00366-8 · Cited by 27
High-density lipoprotein-related cholesterol metabolism in Alzheimer's disease
Pedrini, S., Chatterjee, P., Hone, E., & Martins, R. N. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15170 · Cited by 22
(2022) · doi:10.3390/proteomes10030026 · Cited by 20
Xu, C., Garcia, D., Lu, Y., Ozuna, K., Adjeroh, D. A., Wang, K., & Initiative, O. B. O. T. A. D. N. (2021) · Cells · doi:10.3390/cells11010029 · Cited by 19
Hu, Y., Meuret, C., Martinez, A., Yassine, H. N., & Nedelkov, D. (2021) · Journal of Lipid Research · doi:10.1194/jlr.ra120000919 · Cited by 18
Metadata
- Authors
- Shih, Y.-H., Tsai, K.-J., Lee, C.-W., Shiesh, S.-C., Chen, W.-T., Pai, M.-C., & Kuo, Y.-M.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2014-07-16
- Volume
- 41
- Issue
- 3
- Pages
- 855-865
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W1563224649
- Cited by
- 70
- References
- 15
- FWCI
- 2.92
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.